Effectiveness of alendronate therapy in the cystic fibrosis patient with osteoporosis. Alendronate has been useful in preventing bone loss in a variety of patient groups including steroid treated patients. It is unknown whether this agent is effective in preventing bone loss in the high risk population of cystic fibrosis patients. Studies to determine its efficacy as well as safety in this population are ongoing. Prevention of osteoporosis with once weekly alendronate in the pancreas and pancreas kidney transplant patient.
Osteoporosis is a common consequence of organ transplantation.
Bisphosphonate medications have been used to prevent bone loss in steroid treated patients. A prospective trial to determine if once weekly alendronate will prevent bone loss in the pancreas and pancreas kidney transplant patients is planned. It is currently unknown whether or not growth hormone therapy has an overall greater potential benefit in adult patients who are growth hormone deficient. Relaxin is a polypeptide hormone in the insulin family. The most well-characterized function of relaxin is in pregnancy, where it is involved in connective tissue rearrangement.